This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
About
Before and After Patient images
Clinical study: ALLEGRO 2b/3. Outcome reported: SALT score ≤10 (90% or more scalp hair coverage) at Week 24. Dose: Litfulo 50mg once daily.
These are real patient case studies, however, not all patients treated with Litfulo will respond and individual results will vary.
Limitations: SALT score assessment may be subjective as it is investigator dependent and the full extent of an individual’s hair loss may not be completely represented in photographs.
Right
Left
Top
Example
Back
Clinical study: ALLEGRO 2b/3. Outcome reported: SALT score ≤20 (80% or more scalp hair coverage) at Week 24. Dose: Litfulo 50mg once daily.
These are real patient case studies, however, not all patients treated with Litfulo will respond and individual results will vary.
Limitations: SALT score assessment may be subjective as it is investigator dependent and the full extent of an individual’s hair loss may not be completely represented in photographs.
Right
Left
Top
Back
Litfulo is contraindicated in pregnancy and breast-feeding. Litfulo is not recommended in women of childbearing potential not using contraception. Women of reproductive potential have to use effective contraception during treatment and for 1 month following the final dose of Litfulo. The effect of Litfulo on human fertility has not been evaluated.2
Learn about the safety profile of Litfulo, including contraindications and Adverse Reactions
Read Litfulo's Safety Profile
Read our guide detailing what a SALT score is and how it is calculated
Download SALT score guide
Screening and monitoring guidance to consider when initiating treatment with Litfulo
Download Litfulo initiation guide
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.